Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $1.6 billion.

  • Collegium Pharmaceutical's Liabilities and Shareholders Equity fell 170.17% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 billion, marking a year-over-year increase of 3131.43%. This contributed to the annual value of $1.7 billion for FY2024, which is 4550.68% up from last year.
  • According to the latest figures from Q3 2025, Collegium Pharmaceutical's Liabilities and Shareholders Equity is $1.6 billion, which was down 170.17% from $1.6 billion recorded in Q2 2025.
  • Collegium Pharmaceutical's 5-year Liabilities and Shareholders Equity high stood at $1.7 billion for Q4 2024, and its period low was $646.1 million during Q1 2021.
  • In the last 5 years, Collegium Pharmaceutical's Liabilities and Shareholders Equity had a median value of $1.2 billion in 2022 and averaged $1.2 billion.
  • Per our database at Business Quant, Collegium Pharmaceutical's Liabilities and Shareholders Equity skyrocketed by 9288.17% in 2022 and then tumbled by 1322.37% in 2024.
  • Quarter analysis of 5 years shows Collegium Pharmaceutical's Liabilities and Shareholders Equity stood at $692.1 million in 2021, then skyrocketed by 69.65% to $1.2 billion in 2022, then fell by 2.63% to $1.1 billion in 2023, then soared by 45.51% to $1.7 billion in 2024, then dropped by 3.38% to $1.6 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.6 billion for Q3 2025, versus $1.6 billion for Q2 2025 and $1.6 billion for Q1 2025.